# pathway_0122: before and after transfer clarification

[All 1,328 cases](../README.md) · [Method](../METHOD.md) · [Summary](../SUMMARY.md) · [Exact reviewer user message](../inputs/pathway_0122.txt)

**Task:** `pathway`  
**Author key, unchanged:** **A** — Purine metabolism

| Round | Reviewer | Key support | Transfer / lookup | Output usability (canonical status) |
|---|---|---|---|---|
| before | GPT-6 Luna | supported | lookup-dependent | usable output (valid_review) |
| before | Qwen3.8-Flash-Next-NVFP4 | supported | reasoning-supported | usable output (valid_review) |
| after | GPT-6 Luna | supported | reasoning-supported | usable output (valid_review) |
| after | Qwen3.8-Flash-Next-NVFP4 | supported | reasoning-supported | usable output (valid_review) |

**Usable output means format-valid review, not reasoning-supported or biologically correct.** A usable output can classify the question as reasoning-supported, lookup-dependent or uncertain. An output error is a problem with the saved model response; it does not count a defective benchmark question or wrong key. Each saved review is retained in full below. Labels from output errors are displayed as saved and excluded from label statistics. The author key and reviewer evidence were visible to reviewers; this is a review of answerability and key support, not a benchmark-solving score.

## Complete original question

```text
[Protein Sequence]
MCGVLALILANQSSSAANDLHEALYVLQHRGQDAAGIATSTSSGHIHIRKKNGMAADVFQSGARLANLFGSMGIAHLRYPTAGGSANTEAQPFYVNSPYGICFAHNGNLINTVELRRYLDFEIHRHINSDSDSELMLNIFADELSETKKARVNTEDIFNGLSKMYQRCEGAWACTAMLAGFGVIGFRDAYGIRPLVMGSRPSSDGDGLDYMIASESIALDRLGFTNVRDIQPGEAVIVAKGAEPVFCQVAPRKSYTPDLFEYVYFARPDSVIDGISVYQSRQRMGRYLAARLLEVLGPEGIKEIDVVIPVPETSSPAAASVAHALNKPYCAGYIRNPYVFRTFIMPGQATRQKGVRRKLSAVKEEFKNRTILLVDDSIARGTTSREAISMAREAGVKKIIAACCSPEITYPHIYGIDLPSPHEMVAYERDNNDIAQNLGADRIVYQTLEDLQASCAEIARENDFQEPHTFENGVFSGQYVTPVPEGYFALLEKIRGTGRKEALDKSSKRL

[Multiple Choices]
A. Purine metabolism
B. Cofactor biosynthesis
C. CoA from (R)-pantothenate: step 3/5. .
D. peptidoglycan biosynthesis. .
```

<details>
<summary>Complete original system instructions</summary>

```text
You are an excellent scientist. Analyze the provided protein-related task carefully and choose the correct answer from the multiple-choice options.

The current task is about Protein Pathway Prediction, which is to predict the primary metabolic or signaling pathway in which a given protein functions. Biological pathways are series of chemical reactions occurring within a cell that are essential for life. Based on the protein's amino acid sequence, you should identify the most relevant pathway from the given options.. The inputs provided by the user for this task include:

* Protein Sequence: The amino acid sequence of the protein.
* Multiple Choices: Candidate answers for the protein-related question.

Please think step-by-step about this problem:
1. Analyze the protein sequence carefully.
2. Consider the biological context and function.
3. Evaluate each multiple-choice option.
4. Provide your reasoning process.
5. Finally, give your answer.

Provide your response in the following format:
1. reasoning: [Your detailed reasoning here]
2. answer: Your final answer, which should be "A", "B", "C" or "D".
```

</details>

## Four saved visible reviews

## Before: GPT-6 Luna

**Output usability:** usable output: format-valid review.
**Canonical saved status:** `valid_review`.

### Expected-answer support: supported

> The exact sequence matches a UniProt entry annotated as phosphoribosylpyrophosphate amidotransferase FrzK (EC 2.4.2.14), with a pathway annotation placing it in de novo purine/IMP biosynthesis. The enzyme annotation cites functional evidence; the pathway annotation is separately marked as curated evidence, so it should not be treated as a direct experimental measurement of pathway membership.

Citations as saved: [C1](#evidence-c1), [C4](#evidence-c4), [C5](#evidence-c5), [H3](#evidence-h3).

### Reasoning versus lookup: lookup-dependent

**Discriminating biological argument**

> Identifying a glutamine-dependent phosphoribosylpyrophosphate amidotransferase from the sequence would point toward de novo purine biosynthesis, but the input does not provide that protein-family or enzyme identification.


**Missing item-specific fact**

> The protein-specific assignment of this sequence to phosphoribosylpyrophosphate amidotransferase FrzK and its associated pathway is needed to select A.


**Reason**

> The raw sequence and choices do not directly state the enzyme function or pathway. Distinguishing A relies on identifying this particular sequence through domain/homology knowledge or an external annotation; simply recalling or retrieving its database entry is not reasoning supplied by the question.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[]
```

> The sequence-matched annotation supports purine metabolism; no supplied evidence supports another listed pathway.


### Important caveats

- The historical and current records both match the supplied sequence, but the author's exact source snapshot is unknown.
- The pathway annotation is curated evidence (ECO:0000305), while the enzyme EC annotation cites functional evidence (ECO:0000269); these evidence types should not be conflated.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "Identifying a glutamine-dependent phosphoribosylpyrophosphate amidotransferase from the sequence would point toward de novo purine biosynthesis, but the input does not provide that protein-family or enzyme identification.",
    "judgment": "lookup_or_memorization_dependent",
    "missing_item_specific_fact": "The protein-specific assignment of this sequence to phosphoribosylpyrophosphate amidotransferase FrzK and its associated pathway is needed to select A.",
    "reason": "The raw sequence and choices do not directly state the enzyme function or pathway. Distinguishing A relies on identifying this particular sequence through domain/homology knowledge or an external annotation; simply recalling or retrieving its database entry is not reasoning supplied by the question."
  },
  "case_id": "pathway_0122",
  "expected_answer_check": {
    "evidence_ids": [
      "C1",
      "C4",
      "C5",
      "H3"
    ],
    "judgment": "supported",
    "reason": "The exact sequence matches a UniProt entry annotated as phosphoribosylpyrophosphate amidotransferase FrzK (EC 2.4.2.14), with a pathway annotation placing it in de novo purine/IMP biosynthesis. The enzyme annotation cites functional evidence; the pathway annotation is separately marked as curated evidence, so it should not be treated as a direct experimental measurement of pathway membership."
  },
  "important_caveats": [
    "The historical and current records both match the supplied sequence, but the author's exact source snapshot is unknown.",
    "The pathway annotation is curated evidence (ECO:0000305), while the enzyme EC annotation cites functional evidence (ECO:0000269); these evidence types should not be conflated."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The sequence-matched annotation supports purine metabolism; no supplied evidence supports another listed pathway."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text
{
  "case_id": "pathway_0122",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The exact sequence matches a UniProt entry annotated as phosphoribosylpyrophosphate amidotransferase FrzK (EC 2.4.2.14), with a pathway annotation placing it in de novo purine/IMP biosynthesis. The enzyme annotation cites functional evidence; the pathway annotation is separately marked as curated evidence, so it should not be treated as a direct experimental measurement of pathway membership.",
    "evidence_ids": ["C1", "C4", "C5", "H3"]
  },
  "answerability_check": {
    "judgment": "lookup_or_memorization_dependent",
    "discriminating_biological_argument": "Identifying a glutamine-dependent phosphoribosylpyrophosphate amidotransferase from the sequence would point toward de novo purine biosynthesis, but the input does not provide that protein-family or enzyme identification.",
    "missing_item_specific_fact": "The protein-specific assignment of this sequence to phosphoribosylpyrophosphate amidotransferase FrzK and its associated pathway is needed to select A.",
    "reason": "The raw sequence and choices do not directly state the enzyme function or pathway. Distinguishing A relies on identifying this particular sequence through domain/homology knowledge or an external annotation; simply recalling or retrieving its database entry is not reasoning supplied by the question."
  },
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The sequence-matched annotation supports purine metabolism; no supplied evidence supports another listed pathway."
  },
  "important_caveats": [
    "The historical and current records both match the supplied sequence, but the author's exact source snapshot is unknown.",
    "The pathway annotation is curated evidence (ECO:0000305), while the enzyme EC annotation cites functional evidence (ECO:0000269); these evidence types should not be conflated."
  ]
}
```

</details>

## Before: Qwen3.8-Flash-Next-NVFP4

**Output usability:** usable output: format-valid review.
**Canonical saved status:** `valid_review`.

### Expected-answer support: supported

> The UniProt annotation (A0A7T8J1U7, sequence matched exactly) explicitly states the pathway as 'Purine metabolism; IMP biosynthesis via de novo pathway; N(1)-(5-phospho-D-ribosyl)glycinamide from 5-phospho-alpha-D-ribose 1-diphosphate: step 1/2' with evidence code ECO:0000305 from PubMed:33372776. The enzyme is named Phosphoribosylpyrophosphate amidotransferase FrzK (EC 2.4.2.14), which catalyzes the first committed step of de novo purine biosynthesis. Choice A 'Purine metabolism' directly matches this annotation.

Citations as saved: [C4](#evidence-c4), [C5](#evidence-c5), [H1](#evidence-h1), [H3](#evidence-h3).

### Reasoning versus lookup: reasoning-supported

**Discriminating biological argument**

> The sequence contains a recognizable class I glutamine amidotransferase (GAT) domain motif (the 'GAWACT' sequence around residues ~140-150) combined with a PRPP-binding domain architecture in a single polypeptide. This GAT + PRPP-binding tandem arrangement is the hallmark structural signature of phosphoribosylpyrophosphate amidotransferase (PurF-type), which catalyzes the first committed step of de novo purine (IMP) biosynthesis. Peptidoglycan biosynthesis (D) involves Mur ligases/transpeptidases with entirely different domain architectures. CoA biosynthesis from pantothenate (C) involves pantothenate kinase, phosphopantothenate synthetase, and CoA synthase — none of which are GAT+PRPP enzymes. Cofactor biosynthesis (B) is vague but GAT+PRPP single-chain enzymes are not characteristic of common cofactor pathways (NAD, FAD, etc.).


**Missing item-specific fact**

> None strictly required. The domain-architecture argument (GAT motif + PRPP-binding domain in one polypeptide → PurF-type → purine biosynthesis) is general biochemistry. A model would not need to recall the specific UniProt entry or the FR901483 paper.


**Reason**

> A biologist familiar with amidotransferase domain families can identify the GAWACT GAT motif and the PRPP-binding fold in the sequence, then use the well-established rule that a single-chain GAT+PRPP enzyme is a phosphoribosylpyrophosphate amidotransferase functioning in de novo purine biosynthesis. The distractors are eliminated by incompatible domain architectures. This constitutes concrete reasoning from sequence features rather than memorization of a database entry.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[]
```

> The four choices target distinct biochemical pathways with incompatible enzyme architectures. The GAT+PRPP single-polypeptide signature specifically points to purine biosynthesis and does not fit peptidoglycan, CoA-from-pantothenate, or generic cofactor pathways. The protein's role in FR901483 natural-product biosynthesis is not offered as a distractor, so no ambiguity arises from its dual annotation context.


### Important caveats

- The protein was originally characterized in the FR901483 immunosuppressant biosynthesis cluster (PubMed:33372776). Its biological role in Cladobotryum sp. may be specifically for FR901483 biosynthesis rather than general purine metabolism, but UniProt and the EC classification place it under 'Purine metabolism' because the catalytic reaction (PRPP → 5-phospho-β-D-ribosylamine) is the same purine-biosynthetic step.
- The GAT domain is shared across many amidotransferases (HisH, TrpG, PyrG, etc.); the specific assignment to purine biosynthesis relies on recognizing the PRPP-binding domain co-occurrence, which is a well-established but non-trivial inference.
- All reviewer evidence is from UniProt annotation (ECO:0000305 curator inference from publication); no independent enzymatic assay data was provided in the evidence excerpts.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "The sequence contains a recognizable class I glutamine amidotransferase (GAT) domain motif (the 'GAWACT' sequence around residues ~140-150) combined with a PRPP-binding domain architecture in a single polypeptide. This GAT + PRPP-binding tandem arrangement is the hallmark structural signature of phosphoribosylpyrophosphate amidotransferase (PurF-type), which catalyzes the first committed step of de novo purine (IMP) biosynthesis. Peptidoglycan biosynthesis (D) involves Mur ligases/transpeptidases with entirely different domain architectures. CoA biosynthesis from pantothenate (C) involves pantothenate kinase, phosphopantothenate synthetase, and CoA synthase — none of which are GAT+PRPP enzymes. Cofactor biosynthesis (B) is vague but GAT+PRPP single-chain enzymes are not characteristic of common cofactor pathways (NAD, FAD, etc.).",
    "judgment": "reasoning_supported",
    "missing_item_specific_fact": "None strictly required. The domain-architecture argument (GAT motif + PRPP-binding domain in one polypeptide → PurF-type → purine biosynthesis) is general biochemistry. A model would not need to recall the specific UniProt entry or the FR901483 paper.",
    "reason": "A biologist familiar with amidotransferase domain families can identify the GAWACT GAT motif and the PRPP-binding fold in the sequence, then use the well-established rule that a single-chain GAT+PRPP enzyme is a phosphoribosylpyrophosphate amidotransferase functioning in de novo purine biosynthesis. The distractors are eliminated by incompatible domain architectures. This constitutes concrete reasoning from sequence features rather than memorization of a database entry."
  },
  "case_id": "pathway_0122",
  "expected_answer_check": {
    "evidence_ids": [
      "C4",
      "C5",
      "H1",
      "H3"
    ],
    "judgment": "supported",
    "reason": "The UniProt annotation (A0A7T8J1U7, sequence matched exactly) explicitly states the pathway as 'Purine metabolism; IMP biosynthesis via de novo pathway; N(1)-(5-phospho-D-ribosyl)glycinamide from 5-phospho-alpha-D-ribose 1-diphosphate: step 1/2' with evidence code ECO:0000305 from PubMed:33372776. The enzyme is named Phosphoribosylpyrophosphate amidotransferase FrzK (EC 2.4.2.14), which catalyzes the first committed step of de novo purine biosynthesis. Choice A 'Purine metabolism' directly matches this annotation."
  },
  "important_caveats": [
    "The protein was originally characterized in the FR901483 immunosuppressant biosynthesis cluster (PubMed:33372776). Its biological role in Cladobotryum sp. may be specifically for FR901483 biosynthesis rather than general purine metabolism, but UniProt and the EC classification place it under 'Purine metabolism' because the catalytic reaction (PRPP → 5-phospho-β-D-ribosylamine) is the same purine-biosynthetic step.",
    "The GAT domain is shared across many amidotransferases (HisH, TrpG, PyrG, etc.); the specific assignment to purine biosynthesis relies on recognizing the PRPP-binding domain co-occurrence, which is a well-established but non-trivial inference.",
    "All reviewer evidence is from UniProt annotation (ECO:0000305 curator inference from publication); no independent enzymatic assay data was provided in the evidence excerpts."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The four choices target distinct biochemical pathways with incompatible enzyme architectures. The GAT+PRPP single-polypeptide signature specifically points to purine biosynthesis and does not fit peptidoglycan, CoA-from-pantothenate, or generic cofactor pathways. The protein's role in FR901483 natural-product biosynthesis is not offered as a distractor, so no ambiguity arises from its dual annotation context."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text


{
  "case_id": "pathway_0122",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The UniProt annotation (A0A7T8J1U7, sequence matched exactly) explicitly states the pathway as 'Purine metabolism; IMP biosynthesis via de novo pathway; N(1)-(5-phospho-D-ribosyl)glycinamide from 5-phospho-alpha-D-ribose 1-diphosphate: step 1/2' with evidence code ECO:0000305 from PubMed:33372776. The enzyme is named Phosphoribosylpyrophosphate amidotransferase FrzK (EC 2.4.2.14), which catalyzes the first committed step of de novo purine biosynthesis. Choice A 'Purine metabolism' directly matches this annotation.",
    "evidence_ids": ["C4", "C5", "H1", "H3"]
  },
  "answerability_check": {
    "judgment": "reasoning_supported",
    "discriminating_biological_argument": "The sequence contains a recognizable class I glutamine amidotransferase (GAT) domain motif (the 'GAWACT' sequence around residues ~140-150) combined with a PRPP-binding domain architecture in a single polypeptide. This GAT + PRPP-binding tandem arrangement is the hallmark structural signature of phosphoribosylpyrophosphate amidotransferase (PurF-type), which catalyzes the first committed step of de novo purine (IMP) biosynthesis. Peptidoglycan biosynthesis (D) involves Mur ligases/transpeptidases with entirely different domain architectures. CoA biosynthesis from pantothenate (C) involves pantothenate kinase, phosphopantothenate synthetase, and CoA synthase — none of which are GAT+PRPP enzymes. Cofactor biosynthesis (B) is vague but GAT+PRPP single-chain enzymes are not characteristic of common cofactor pathways (NAD, FAD, etc.).",
    "missing_item_specific_fact": "None strictly required. The domain-architecture argument (GAT motif + PRPP-binding domain in one polypeptide → PurF-type → purine biosynthesis) is general biochemistry. A model would not need to recall the specific UniProt entry or the FR901483 paper.",
    "reason": "A biologist familiar with amidotransferase domain families can identify the GAWACT GAT motif and the PRPP-binding fold in the sequence, then use the well-established rule that a single-chain GAT+PRPP enzyme is a phosphoribosylpyrophosphate amidotransferase functioning in de novo purine biosynthesis. The distractors are eliminated by incompatible domain architectures. This constitutes concrete reasoning from sequence features rather than memorization of a database entry."
  },
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The four choices target distinct biochemical pathways with incompatible enzyme architectures. The GAT+PRPP single-polypeptide signature specifically points to purine biosynthesis and does not fit peptidoglycan, CoA-from-pantothenate, or generic cofactor pathways. The protein's role in FR901483 natural-product biosynthesis is not offered as a distractor, so no ambiguity arises from its dual annotation context."
  },
  "important_caveats": [
    "The protein was originally characterized in the FR901483 immunosuppressant biosynthesis cluster (PubMed:33372776). Its biological role in Cladobotryum sp. may be specifically for FR901483 biosynthesis rather than general purine metabolism, but UniProt and the EC classification place it under 'Purine metabolism' because the catalytic reaction (PRPP → 5-phospho-β-D-ribosylamine) is the same purine-biosynthetic step.",
    "The GAT domain is shared across many amidotransferases (HisH, TrpG, PyrG, etc.); the specific assignment to purine biosynthesis relies on recognizing the PRPP-binding domain co-occurrence, which is a well-established but non-trivial inference.",
    "All reviewer evidence is from UniProt annotation (ECO:0000305 curator inference from publication); no independent enzymatic assay data was provided in the evidence excerpts."
  ]
}
```

</details>

## After: GPT-6 Luna

**Output usability:** usable output: format-valid review.
**Canonical saved status:** `valid_review`.

### Expected-answer support: supported

> The sequence-matched UniProt annotation identifies the protein as phosphoribosylpyrophosphate amidotransferase and places it in de novo purine/IMP biosynthesis, supporting option A. The pathway annotation cites a publication; the excerpt alone does not establish that the pathway assignment was directly experimentally demonstrated.

Citations as saved: [C4](#evidence-c4), [C5](#evidence-c5), [H3](#evidence-h3).

### Reasoning versus lookup: reasoning-supported

**Discriminating biological argument**

> The sequence is consistent with a glutamine phosphoribosylpyrophosphate amidotransferase (PurF/ATase) family enzyme. Such enzymes use glutamine and PRPP in the first committed step of de novo purine biosynthesis, which distinguishes purine metabolism (A) from cofactor biosynthesis, CoA synthesis, and peptidoglycan biosynthesis.


**Missing item-specific fact**

Empty string, as saved.


**Reason**

> Family-level recognition and the conserved enzyme role provide a meaningful transferable inference from the sequence to the offered pathway choices. This does not require recalling the exact protein's database record.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[]
```

> The enzyme family’s canonical pathway is represented by option A; none of the other options describes its stated biosynthetic role.


### Important caveats

- The sequence-matched database pathway annotation is cited to a publication, but the supplied excerpts do not independently establish the experimental basis for every detail of that annotation.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "The sequence is consistent with a glutamine phosphoribosylpyrophosphate amidotransferase (PurF/ATase) family enzyme. Such enzymes use glutamine and PRPP in the first committed step of de novo purine biosynthesis, which distinguishes purine metabolism (A) from cofactor biosynthesis, CoA synthesis, and peptidoglycan biosynthesis.",
    "judgment": "reasoning_supported",
    "missing_item_specific_fact": "",
    "reason": "Family-level recognition and the conserved enzyme role provide a meaningful transferable inference from the sequence to the offered pathway choices. This does not require recalling the exact protein's database record."
  },
  "case_id": "pathway_0122",
  "expected_answer_check": {
    "evidence_ids": [
      "C4",
      "C5",
      "H3"
    ],
    "judgment": "supported",
    "reason": "The sequence-matched UniProt annotation identifies the protein as phosphoribosylpyrophosphate amidotransferase and places it in de novo purine/IMP biosynthesis, supporting option A. The pathway annotation cites a publication; the excerpt alone does not establish that the pathway assignment was directly experimentally demonstrated."
  },
  "important_caveats": [
    "The sequence-matched database pathway annotation is cited to a publication, but the supplied excerpts do not independently establish the experimental basis for every detail of that annotation."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The enzyme family’s canonical pathway is represented by option A; none of the other options describes its stated biosynthetic role."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text
{
  "case_id": "pathway_0122",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The sequence-matched UniProt annotation identifies the protein as phosphoribosylpyrophosphate amidotransferase and places it in de novo purine/IMP biosynthesis, supporting option A. The pathway annotation cites a publication; the excerpt alone does not establish that the pathway assignment was directly experimentally demonstrated.",
    "evidence_ids": ["C4", "C5", "H3"]
  },
  "answerability_check": {
    "judgment": "reasoning_supported",
    "discriminating_biological_argument": "The sequence is consistent with a glutamine phosphoribosylpyrophosphate amidotransferase (PurF/ATase) family enzyme. Such enzymes use glutamine and PRPP in the first committed step of de novo purine biosynthesis, which distinguishes purine metabolism (A) from cofactor biosynthesis, CoA synthesis, and peptidoglycan biosynthesis.",
    "missing_item_specific_fact": "",
    "reason": "Family-level recognition and the conserved enzyme role provide a meaningful transferable inference from the sequence to the offered pathway choices. This does not require recalling the exact protein's database record."
  },
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The enzyme family’s canonical pathway is represented by option A; none of the other options describes its stated biosynthetic role."
  },
  "important_caveats": [
    "The sequence-matched database pathway annotation is cited to a publication, but the supplied excerpts do not independently establish the experimental basis for every detail of that annotation."
  ]
}
```

</details>

## After: Qwen3.8-Flash-Next-NVFP4

**Output usability:** usable output: format-valid review.
**Canonical saved status:** `valid_review`.

### Expected-answer support: supported

> The UniProt entry (A0A7T8J1U7) explicitly annotates the pathway as 'Purine metabolism; IMP biosynthesis via de novo pathway; N(1)-(5-phospho-D-ribosyl)glycinamide from 5-phospho-alpha-D-ribose 1-diphosphate: step 1/2' (evidence C5, H3). The enzyme is a glutamine phosphoribosylpyrophosphate amidotransferase (EC 2.4.2.14), which catalyzes the first committed step in de novo purine biosynthesis. The expected answer 'Purine metabolism' is directly supported by the database annotation.

Citations as saved: [C5](#evidence-c5), [H3](#evidence-h3), [C4](#evidence-c4).

### Reasoning versus lookup: reasoning-supported

**Discriminating biological argument**

> The protein is ~510 amino acids and contains a glutamine amidotransferase (GAT) class I domain (identifiable by the Cys-His-Asp catalytic triad region and characteristic motifs around residues ~380-430, e.g., 'CCSPEITYPHIYGIDLPSPHEM...') combined with a PRPP-binding domain architecture. This specific GAT + PRPP-binding two-domain architecture at ~500-550 aa is the hallmark of the PRPP amidotransferase (PurF) family, which catalyzes the first committed step of de novo purine biosynthesis (PRPP → 5-phosphoribosylamine). This is well-established textbook knowledge transferable from canonical PurF enzymes in E. coli, yeast, and other organisms. Option C (CoA biosynthesis step 3/5) involves small enzymes like phosphopantothenoylcysteine synthetase (~200-300 aa) with entirely different domains. Option D (peptidoglycan biosynthesis) involves transglycosylases/transpeptidases with completely different architectures and is bacterial-specific. Option B (cofactor biosynthesis) is overly broad, but the specific PRPP+GAT combination is not characteristic of common cofactor pathways (folate, NAD, CoA) and instead uniquely identifies purine biosynthesis. A knowledgeable model recognizing the GAT+PRPP architecture would select purine metabolism over the alternatives.


**Missing item-specific fact**

Empty string, as saved.


**Reason**

> The GAT + PRPP-binding two-domain architecture at ~510 aa is a well-characterized family-level signature (PRPP amidotransferase family) that a model can recognize from homologs and textbook knowledge of purine biosynthesis. This meaningfully distinguishes option A from the other three choices without requiring knowledge of this exact protein's annotation.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[]
```

> The four options are well-separated by domain architecture and pathway logic. CoA biosynthesis (C) and peptidoglycan biosynthesis (D) require entirely different enzyme families. Cofactor biosynthesis (B) is too broad and does not match the specific PRPP+GAT signature. Purine metabolism (A) is the clear best fit for a GAT+PRPP-binding enzyme of this size.


### Important caveats

- This protein (FrzK, EC 2.4.2.14) is part of the FR901483 immunosuppressant biosynthetic cluster in Cladobotryum sp., not the canonical PurF (EC 6.3.4.18). However, it catalyzes the same chemical reaction (PRPP + glutamine → 5-phosphoribosylamine) and is annotated in the purine metabolism pathway.
- The GAT domain is shared across many amidotransferases (CPS, FGAM synthase, etc.), so recognition of GAT alone is insufficient; the combination with a PRPP-binding domain at this molecular weight is what specifically points to purine biosynthesis.
- The model cannot know from the sequence alone that the organism is a fungus (which would exclude peptidoglycan biosynthesis), but the domain architecture argument independently rules out option D.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "The protein is ~510 amino acids and contains a glutamine amidotransferase (GAT) class I domain (identifiable by the Cys-His-Asp catalytic triad region and characteristic motifs around residues ~380-430, e.g., 'CCSPEITYPHIYGIDLPSPHEM...') combined with a PRPP-binding domain architecture. This specific GAT + PRPP-binding two-domain architecture at ~500-550 aa is the hallmark of the PRPP amidotransferase (PurF) family, which catalyzes the first committed step of de novo purine biosynthesis (PRPP → 5-phosphoribosylamine). This is well-established textbook knowledge transferable from canonical PurF enzymes in E. coli, yeast, and other organisms. Option C (CoA biosynthesis step 3/5) involves small enzymes like phosphopantothenoylcysteine synthetase (~200-300 aa) with entirely different domains. Option D (peptidoglycan biosynthesis) involves transglycosylases/transpeptidases with completely different architectures and is bacterial-specific. Option B (cofactor biosynthesis) is overly broad, but the specific PRPP+GAT combination is not characteristic of common cofactor pathways (folate, NAD, CoA) and instead uniquely identifies purine biosynthesis. A knowledgeable model recognizing the GAT+PRPP architecture would select purine metabolism over the alternatives.",
    "judgment": "reasoning_supported",
    "missing_item_specific_fact": "",
    "reason": "The GAT + PRPP-binding two-domain architecture at ~510 aa is a well-characterized family-level signature (PRPP amidotransferase family) that a model can recognize from homologs and textbook knowledge of purine biosynthesis. This meaningfully distinguishes option A from the other three choices without requiring knowledge of this exact protein's annotation."
  },
  "case_id": "pathway_0122",
  "expected_answer_check": {
    "evidence_ids": [
      "C5",
      "H3",
      "C4"
    ],
    "judgment": "supported",
    "reason": "The UniProt entry (A0A7T8J1U7) explicitly annotates the pathway as 'Purine metabolism; IMP biosynthesis via de novo pathway; N(1)-(5-phospho-D-ribosyl)glycinamide from 5-phospho-alpha-D-ribose 1-diphosphate: step 1/2' (evidence C5, H3). The enzyme is a glutamine phosphoribosylpyrophosphate amidotransferase (EC 2.4.2.14), which catalyzes the first committed step in de novo purine biosynthesis. The expected answer 'Purine metabolism' is directly supported by the database annotation."
  },
  "important_caveats": [
    "This protein (FrzK, EC 2.4.2.14) is part of the FR901483 immunosuppressant biosynthetic cluster in Cladobotryum sp., not the canonical PurF (EC 6.3.4.18). However, it catalyzes the same chemical reaction (PRPP + glutamine → 5-phosphoribosylamine) and is annotated in the purine metabolism pathway.",
    "The GAT domain is shared across many amidotransferases (CPS, FGAM synthase, etc.), so recognition of GAT alone is insufficient; the combination with a PRPP-binding domain at this molecular weight is what specifically points to purine biosynthesis.",
    "The model cannot know from the sequence alone that the organism is a fungus (which would exclude peptidoglycan biosynthesis), but the domain architecture argument independently rules out option D."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The four options are well-separated by domain architecture and pathway logic. CoA biosynthesis (C) and peptidoglycan biosynthesis (D) require entirely different enzyme families. Cofactor biosynthesis (B) is too broad and does not match the specific PRPP+GAT signature. Purine metabolism (A) is the clear best fit for a GAT+PRPP-binding enzyme of this size."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text


{
  "case_id": "pathway_0122",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The UniProt entry (A0A7T8J1U7) explicitly annotates the pathway as 'Purine metabolism; IMP biosynthesis via de novo pathway; N(1)-(5-phospho-D-ribosyl)glycinamide from 5-phospho-alpha-D-ribose 1-diphosphate: step 1/2' (evidence C5, H3). The enzyme is a glutamine phosphoribosylpyrophosphate amidotransferase (EC 2.4.2.14), which catalyzes the first committed step in de novo purine biosynthesis. The expected answer 'Purine metabolism' is directly supported by the database annotation.",
    "evidence_ids": ["C5", "H3", "C4"]
  },
  "answerability_check": {
    "judgment": "reasoning_supported",
    "discriminating_biological_argument": "The protein is ~510 amino acids and contains a glutamine amidotransferase (GAT) class I domain (identifiable by the Cys-His-Asp catalytic triad region and characteristic motifs around residues ~380-430, e.g., 'CCSPEITYPHIYGIDLPSPHEM...') combined with a PRPP-binding domain architecture. This specific GAT + PRPP-binding two-domain architecture at ~500-550 aa is the hallmark of the PRPP amidotransferase (PurF) family, which catalyzes the first committed step of de novo purine biosynthesis (PRPP → 5-phosphoribosylamine). This is well-established textbook knowledge transferable from canonical PurF enzymes in E. coli, yeast, and other organisms. Option C (CoA biosynthesis step 3/5) involves small enzymes like phosphopantothenoylcysteine synthetase (~200-300 aa) with entirely different domains. Option D (peptidoglycan biosynthesis) involves transglycosylases/transpeptidases with completely different architectures and is bacterial-specific. Option B (cofactor biosynthesis) is overly broad, but the specific PRPP+GAT combination is not characteristic of common cofactor pathways (folate, NAD, CoA) and instead uniquely identifies purine biosynthesis. A knowledgeable model recognizing the GAT+PRPP architecture would select purine metabolism over the alternatives.",
    "missing_item_specific_fact": "",
    "reason": "The GAT + PRPP-binding two-domain architecture at ~510 aa is a well-characterized family-level signature (PRPP amidotransferase family) that a model can recognize from homologs and textbook knowledge of purine biosynthesis. This meaningfully distinguishes option A from the other three choices without requiring knowledge of this exact protein's annotation."
  },
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The four options are well-separated by domain architecture and pathway logic. CoA biosynthesis (C) and peptidoglycan biosynthesis (D) require entirely different enzyme families. Cofactor biosynthesis (B) is too broad and does not match the specific PRPP+GAT signature. Purine metabolism (A) is the clear best fit for a GAT+PRPP-binding enzyme of this size."
  },
  "important_caveats": [
    "This protein (FrzK, EC 2.4.2.14) is part of the FR901483 immunosuppressant biosynthetic cluster in Cladobotryum sp., not the canonical PurF (EC 6.3.4.18). However, it catalyzes the same chemical reaction (PRPP + glutamine → 5-phosphoribosylamine) and is annotated in the purine metabolism pathway.",
    "The GAT domain is shared across many amidotransferases (CPS, FGAM synthase, etc.), so recognition of GAT alone is insufficient; the combination with a PRPP-binding domain at this molecular weight is what specifically points to purine biosynthesis.",
    "The model cannot know from the sequence alone that the organism is a fungus (which would exclude peptidoglycan biosynthesis), but the domain architecture argument independently rules out option D."
  ]
}
```

</details>

## Existing project source checks of the old Luna review only

These unchanged notes concern the earlier Luna claims. They do not validate either new review or the old Qwen review. No new scientific adjudication was performed.

## Project source-check notes

These project-authored, AI-assisted checks assess specific source claims. They are not expert adjudication and do not replace Luna’s saved review or the author key.

No additional case-specific project note was recorded. Citation membership checks do not establish that every scientific argument is correct.

## Complete reviewer-only evidence and qualifications

All excerpts supplied in the original and revised reviewer user message follow. This material was not available to the original evaluated model. Accession identity came from dataset image-path metadata. Source support and transferable discrimination are separate judgments.

**Applicability metadata, unchanged:**

```json
{
  "requested_accession": "A0A7T8J1U7",
  "identity_origin": "reviewer-only accession inferred mechanically from original dataset image-path metadata; this accession/metadata was absent from evaluated model input",
  "benchmark_sequence_sha256": "44dc44e51fdf196ccecccc1dbeec4ed51df88981f809d29be8495d6c59ba2224",
  "benchmark_sequence_length": 510,
  "current_status": "retrieved",
  "current_sequence_comparison": "matched",
  "current_entry_audit": {
    "entryVersion": 18,
    "firstPublicDate": "2025-06-18",
    "lastAnnotationUpdateDate": "2026-09-02",
    "lastSequenceUpdateDate": "2021-06-02",
    "sequenceVersion": 1
  },
  "current_uniprot_release": "2026_03",
  "current_record_sha256": "56665e1cd9e3380e3faeac05a356479129623641a0ef275c9308eeccf948063d",
  "current_source_sequence_sha256": "44dc44e51fdf196ccecccc1dbeec4ed51df88981f809d29be8495d6c59ba2224",
  "current_source_sequence_length": 510,
  "historical_status": "retrieved",
  "historical_cutoff_date": "2026-05-07",
  "historical_sequence_comparison": "matched",
  "selected_historical_entry_version": 16,
  "selected_historical_version": {
    "accession": "A0A7T8J1U7",
    "database": "Swiss-Prot",
    "entryVersion": 16,
    "firstRelease": "2026_01/2026_01",
    "firstReleaseDate": "28-Jan-2026",
    "lastRelease": "2026_01/2026_01",
    "lastReleaseDate": "28-Jan-2026",
    "name": "FRZK_CLASX",
    "sequenceVersion": 1
  },
  "selected_historical_record_sha256": "578ee5dbb88bc40f60a644a1dc0fae09acdb5d05f79fe55109621fabea2329a5",
  "selected_historical_source_sequence_sha256": "44dc44e51fdf196ccecccc1dbeec4ed51df88981f809d29be8495d6c59ba2224",
  "selected_historical_source_sequence_length": 510,
  "latest_at_cutoff_sequence_comparison": "matched",
  "historical_sequence_versions_checked": [
    {
      "entry_version": 16,
      "exact_sequence_comparison": "matched",
      "sequence_version": 1
    }
  ],
  "actual_author_source_snapshot": "unknown",
  "numbering": "Canonical entry coordinates; construct or isoform numbering is not assumed."
}
```

**Qualifications, unchanged:**

- All evidence and source identity in this section are reviewer-only and were absent from the evaluated model input.
- UniProt annotations may be experimental, computational, or transferred by similarity; evidence codes and qualifiers are retained.
- The 2026-05-07 cutoff approximates the pinned repository date; the author data-construction date and exact source snapshot remain unknown.
- Selected source fields are excerpts; missing annotation is not evidence of falsehood. Primary papers were not comprehensively retrieved or independently validated.

### Evidence C1

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A7T8J1U7.json)

```json
{
  "evidence_id": "C1",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A7T8J1U7.json",
  "source_sha256": "56665e1cd9e3380e3faeac05a356479129623641a0ef275c9308eeccf948063d",
  "retrieved_utc": "2026-11-02T04:25:51.826168+00:00",
  "json_pointer": "/primaryAccession",
  "excerpt": "\"A0A7T8J1U7\"",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C2

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A7T8J1U7.json)

```json
{
  "evidence_id": "C2",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A7T8J1U7.json",
  "source_sha256": "56665e1cd9e3380e3faeac05a356479129623641a0ef275c9308eeccf948063d",
  "retrieved_utc": "2026-11-02T04:25:51.826168+00:00",
  "json_pointer": "/entryAudit",
  "excerpt": "{\"entryVersion\":18,\"firstPublicDate\":\"2025-06-18\",\"lastAnnotationUpdateDate\":\"2026-09-02\",\"lastSequenceUpdateDate\":\"2021-06-02\",\"sequenceVersion\":1}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C3

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A7T8J1U7.json)

```json
{
  "evidence_id": "C3",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A7T8J1U7.json",
  "source_sha256": "56665e1cd9e3380e3faeac05a356479129623641a0ef275c9308eeccf948063d",
  "retrieved_utc": "2026-11-02T04:25:51.826168+00:00",
  "json_pointer": "/organism",
  "excerpt": "{\"lineage\":[\"Eukaryota\",\"Fungi\",\"Dikarya\",\"Ascomycota\",\"Pezizomycotina\",\"Sordariomycetes\",\"Hypocreomycetidae\",\"Hypocreales\",\"Hypocreaceae\",\"Cladobotryum\"],\"scientificName\":\"Cladobotryum sp\",\"taxonId\":2040732}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C4

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A7T8J1U7.json)

```json
{
  "evidence_id": "C4",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A7T8J1U7.json",
  "source_sha256": "56665e1cd9e3380e3faeac05a356479129623641a0ef275c9308eeccf948063d",
  "retrieved_utc": "2026-11-02T04:25:51.826168+00:00",
  "json_pointer": "/proteinDescription",
  "excerpt": "{\"alternativeNames\":[{\"fullName\":{\"evidences\":[{\"evidenceCode\":\"ECO:0000303\",\"id\":\"33372776\",\"source\":\"PubMed\"}],\"value\":\"FR901483 biosynthesis clusters protein K\"}},{\"fullName\":{\"evidences\":[{\"evidenceCode\":\"ECO:0000303\",\"id\":\"33372776\",\"source\":\"PubMed\"}],\"value\":\"Glutamine phosphoribosylpyrophosphate amidotransferase\"}}],\"recommendedName\":{\"ecNumbers\":[{\"evidences\":[{\"evidenceCode\":\"ECO:0000269\",\"id\":\"33372776\",\"source\":\"PubMed\"}],\"value\":\"2.4.2.14\"}],\"fullName\":{\"evidences\":[{\"evidenceCode\":\"ECO:0000303\",\"id\":\"33372776\",\"source\":\"PubMed\"}],\"value\":\"Phosphoribosylpyrophosphate amidotransferase FrzK\"},\"shortNames\":[{\"evidences\":[{\"evidenceCode\":\"ECO:0000303\",\"id\":\"33372776\",\"source\":\"PubMed\"}],\"value\":\"ATase FrzK\"}]}}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C5

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A7T8J1U7.json)

```json
{
  "evidence_id": "C5",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A7T8J1U7.json",
  "source_sha256": "56665e1cd9e3380e3faeac05a356479129623641a0ef275c9308eeccf948063d",
  "retrieved_utc": "2026-11-02T04:25:51.826168+00:00",
  "json_pointer": "/comments/4",
  "excerpt": "{\"commentType\":\"PATHWAY\",\"texts\":[{\"evidences\":[{\"evidenceCode\":\"ECO:0000305\",\"id\":\"33372776\",\"source\":\"PubMed\"}],\"value\":\"Purine metabolism; IMP biosynthesis via de novo pathway; N(1)-(5-phospho-D-ribosyl)glycinamide from 5-phospho-alpha-D-ribose 1-diphosphate: step 1/2\"}]}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C6

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A7T8J1U7.json)

```json
{
  "evidence_id": "C6",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A7T8J1U7.json",
  "source_sha256": "56665e1cd9e3380e3faeac05a356479129623641a0ef275c9308eeccf948063d",
  "retrieved_utc": "2026-11-02T04:25:51.826168+00:00",
  "json_pointer": "/references/0",
  "excerpt": "{\"citation\":{\"authors\":[\"Zhang Z.\",\"Tamura Y.\",\"Tang M.\",\"Qiao T.\",\"Sato M.\",\"Otsu Y.\",\"Sasamura S.\",\"Taniguchi M.\",\"Watanabe K.\",\"Tang Y.\"],\"citationCrossReferences\":[{\"database\":\"PubMed\",\"id\":\"33372776\"},{\"database\":\"DOI\",\"id\":\"10.1021/jacs.0c12352\"}],\"citationType\":\"journal article\",\"firstPage\":\"132\",\"id\":\"33372776\",\"journal\":\"J. Am. Chem. Soc.\",\"lastPage\":\"136\",\"publicationDate\":\"2021\",\"title\":\"Biosynthesis of the Immunosuppressant (-)-FR901483.\",\"volume\":\"143\"},\"referenceComments\":[{\"type\":\"STRAIN\",\"value\":\"11231\"}],\"referenceNumber\":1,\"referencePositions\":[\"NUCLEOTIDE SEQUENCE [GENOMIC DNA]\",\"FUNCTION\"]}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence H1

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A0A7T8J1U7?format=txt&versions=16)

```json
{
  "evidence_id": "H1",
  "source": "UniSave archived UniProt entry",
  "url": "https://rest.uniprot.org/unisave/A0A7T8J1U7?format=txt&versions=16",
  "source_sha256": "578ee5dbb88bc40f60a644a1dc0fae09acdb5d05f79fe55109621fabea2329a5",
  "retrieved_utc": "2026-11-02T04:25:55.036238+00:00",
  "source_locator": "lines 1-15",
  "excerpt": "ID   FRZK_CLASX              Reviewed;         510 AA.\nAC   A0A7T8J1U7;\nDT   18-JUN-2025, integrated into UniProtKB/Swiss-Prot.\nDT   02-JUN-2021, sequence version 1.\nDT   28-JAN-2026, entry version 16.\nDE   RecName: Full=Phosphoribosylpyrophosphate amidotransferase FrzK {ECO:0000303|PubMed:33372776};\nDE            Short=ATase FrzK {ECO:0000303|PubMed:33372776};\nDE            EC=2.4.2.14 {ECO:0000269|PubMed:33372776};\nDE   AltName: Full=FR901483 biosynthesis clusters protein K {ECO:0000303|PubMed:33372776};\nDE   AltName: Full=Glutamine phosphoribosylpyrophosphate amidotransferase {ECO:0000303|PubMed:33372776};\nGN   Name=FrzK {ECO:0000303|PubMed:33372776};\nOS   Cladobotryum sp.\nOC   Eukaryota; Fungi; Dikarya; Ascomycota; Pezizomycotina; Sordariomycetes;\nOC   Hypocreomycetidae; Hypocreales; Hypocreaceae; Cladobotryum.\nOX   NCBI_TaxID=2040732;\n",
  "excerpt_format": "literal contiguous UniProt flat-file lines",
  "source_scope": "record released no later than 2026-05-07; actual author source snapshot unknown",
  "entry_version": 16,
  "sequence_version": 1,
  "sequence_comparison": "matched"
}
```

### Evidence H2

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A0A7T8J1U7?format=txt&versions=16)

```json
{
  "evidence_id": "H2",
  "source": "UniSave archived UniProt entry",
  "url": "https://rest.uniprot.org/unisave/A0A7T8J1U7?format=txt&versions=16",
  "source_sha256": "578ee5dbb88bc40f60a644a1dc0fae09acdb5d05f79fe55109621fabea2329a5",
  "retrieved_utc": "2026-11-02T04:25:55.036238+00:00",
  "source_locator": "lines 16-23",
  "excerpt": "RN   [1]\nRP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND FUNCTION.\nRC   STRAIN=11231;\nRX   PubMed=33372776; DOI=10.1021/jacs.0c12352;\nRA   Zhang Z., Tamura Y., Tang M., Qiao T., Sato M., Otsu Y., Sasamura S.,\nRA   Taniguchi M., Watanabe K., Tang Y.;\nRT   \"Biosynthesis of the Immunosuppressant (-)-FR901483.\";\nRL   J. Am. Chem. Soc. 143:132-136(2021).\n",
  "excerpt_format": "literal contiguous UniProt flat-file lines",
  "source_scope": "record released no later than 2026-05-07; actual author source snapshot unknown",
  "entry_version": 16,
  "sequence_version": 1,
  "sequence_comparison": "matched"
}
```

### Evidence H3

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A0A7T8J1U7?format=txt&versions=16)

```json
{
  "evidence_id": "H3",
  "source": "UniSave archived UniProt entry",
  "url": "https://rest.uniprot.org/unisave/A0A7T8J1U7?format=txt&versions=16",
  "source_sha256": "578ee5dbb88bc40f60a644a1dc0fae09acdb5d05f79fe55109621fabea2329a5",
  "retrieved_utc": "2026-11-02T04:25:55.036238+00:00",
  "source_locator": "lines 53-55",
  "excerpt": "CC   -!- PATHWAY: Purine metabolism; IMP biosynthesis via de novo pathway; N(1)-\nCC       (5-phospho-D-ribosyl)glycinamide from 5-phospho-alpha-D-ribose 1-\nCC       diphosphate: step 1/2. {ECO:0000305|PubMed:33372776}.\n",
  "excerpt_format": "literal contiguous UniProt flat-file lines",
  "source_scope": "record released no later than 2026-05-07; actual author source snapshot unknown",
  "entry_version": 16,
  "sequence_version": 1,
  "sequence_comparison": "matched"
}
```

---

Original question/key: [pinned source](https://github.com/Rongdingyi/LiveProteinBench/blob/8b9710932511f816651fc1a7e8a1bc85c3c77767/dataset/QA/pathway.json), zero-based source row 122. © 2026 LiveProteinBench contributors; [CC BY 4.0](https://huggingface.co/datasets/LiveProteinBench/LiveProteinBench/blob/8428f64e33d53330f7745376d9c45de2d2c37eaf/LICENSE). [Source credits](../THIRD_PARTY_NOTICES.md).
